Article

Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review

2025-08-15

Abstract excerpt

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are recognised as transformative therapies with complex dermatological profiles, extending beyond their established metabolic benefits. GLP-1 receptors (GLP-1Rs) are present in various tissues, including keratinocytes and immune cells, triggering intracellular signalling. While widely distributed, GLP-1R expression in circulating immune cell populations...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e42a9c08-3e49-56ec-ab5a-bae557feb71b
DOI: 10.22541/au.175521972.20484170/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature reviewDOI 10.22541/au.175521972.20484170/v1Read

Sodium-Glucose Cotransporter-2 Inhibitors and Cutaneous Adverse Reactions: A Systematic Review of Clinical Phenotypes, Time-to- Onset Profiles, and Management Strategies (2020–2026)Semantic proximity Read

The Updated Guide in the Management of Psoriasis for Every PractitionerSemantic proximity Read

Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Semantic proximity Read

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationSemantic proximity Read

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA DatabaseSemantic proximity Read

Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Semantic proximity Read

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity Read

Targeting Metainflammation in Hidradenitis Suppurativa: The Emerging Role of GLP-1 Receptor Agonists and Metabolic PharmacotherapiesSemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read

Severe Cutaneous Adverse Drug Reactions: From Causes to MechanismsSemantic proximity Read

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read